|
[1]LOOMBA R,SANYAL AJ.The global NAFLD epidemic[J].Nat Rev Gastroenterol Hepatol,2013,10(11):686-690.
|
|
[2]YEH MM,BRUNT EM.Pathological features of fatty liver disease[J].Gastroenterology,2014,147(4):754-764.
|
|
[3]de MINICIS S,DAY C,SVEGLIATI-BARONI G.From NAFLD to NASH and HCC:pathogenetic mechanisms and therapeutic insights[J].Curr Pharm Des,2013,19(29):5239-5249.
|
|
[4]DOWMAN JK,TOMLINSON JW,NEWSOME PN.Systematic review:the diagnosis and staging of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis[J].Aliment Pharmacol Ther,2011,33(5):525-540.
|
|
[5]AHMED M.Non-alcoholic fatty liver disease in 2015[J].World J Hepatol,2015,7(11):1450-1459.
|
|
[6]ONIKI K,SARUWATARI J,IZUKA T,et al.Influence of the PNPLA3 rs738409 polymorphism on non-alcoholic fatty liver disease and renal function among normal weight subjects[J].PLo S One,2015,10(7):132640.
|
|
[7]DIXON LJ,BARNES M,TANG H,et al.Kupffer cells in the liver[J].Compr Physiol,2013,3(2):785-797.
|
|
[8]LESTER SN,LI K.Toll-like receptors in antiviral innate immunity[J].J Mol Biol,2014,426(6):1246-1264.
|
|
[9]AVBELJ M,WOLZ OO,FEKONJA O,et al.Activation ol lymphoma-associated My D88 mutations via allostery induced TIR-domain oligomerization[J].Blood,2014,124(26):3896-3904.
|
|
[10]WANG H,LAFDIL F,KONG X,et al.Signal transducer and activator of transcription 3 in liver diseases:a novel therapeutic target[J].Int J Biol,2011,7(5):536-550.
|
|
[11]BIEGHS V,TRAUTWEIN C.Innate immune signaling and gut-liver interactions in non-alcoholic fatty liver disease[J].Hepatobiliary Surg Nutr,2014,3(6):377-385.
|
|
[12]MEDVEDEV AE.Toll-like receptor polymorphisms,inflammatory and infectious diseases,allergies,and cancer[J].J Interferon Cytokine Res,2013,33(9):467-484.
|
|
[13]RAMADORI P,KROY D,STREETZ KL.Immunoregulation by lipids during the development of non-alcoholic steatohepatitis[J].Hepatobiliary Surg Nutr,2015,4(1):11-23.
|
|
[14]LIU M,GUO S,HIBBERT JM,et al.CXCL10/IP-10 in infectious diseases pathogenesis and potential therapeutic implications[J].Cytokine Growth Factor Rev,2011,22(3):121-130.
|
|
[15]IYER SS,CHENG G.Role of interleukin 10 transcriptional regulation in inflammation and autoimmune disease[J].Crit Rev Immunol,2012,32(1):23-63.
|
|
[16]ZHANG X,SHEN J,MAN K,et al.CXCL10 plays a key role as an inflammatory mediator and a non-invasive biomarker of nonalcoholic steatohepatitis[J].J Hepatol,2014,61(6):1365-1375.
|
|
[17]SABAT R,GRTZ G,WARSZAWSKA K,et al.Biology of interleukin-10[J].Cytokine Growth Factor Rev,2010,21(5):331-344.
|
|
[18]RYAN JJ,KASHYAP M,BAILEY D,et al.Mast cell bomeostasis:a fundamental aspect of allergic disease[J].Crit Rev Immunol,2007,27(1):15-32.
|
|
[19]GU QP,BAI AP.Interleukin-10 and inflammatory bowel disease[J].World Chin J Dig,2011,19(1):57-61.(in Chinese)顾秋萍,白爱平.白介素-10与炎症性肠病[J].世界华人消化杂志,2011,19(1):57-61.
|
|
[20]QING Q,ZHOU DS.The variation and significance of serum ratio of IL-18 and IL-10 in NAFLD rats[J].Acta Univ Med Anhui,2013,48(9):1041-1043.(in Chinese)秦清,周冬生.非酒精性脂肪性肝病大鼠血清白介素18、白介素10及其比值的变化和意义[J].安徽医科大学学报,2013,48(9):1041-1043.
|
|
[21]HOLAN V,ZAJICOVA A,JAVORKOVA E,et al.Distinct cytokines balance the development of regulatory T cells and interleukin-10-producing regulatory B cells[J].Immunology,2014,141(4):577-586.
|
|
[22]KONG X,FENG D,MATHEWS S,et al.Hepatoprotective and antifibrotic functions of interleukin-22:therapeutic potential for the treatment of alcoholic liver disease[J].J Gastroenterol Hepatol,2013,28(Suppl 1):56-60.
|
|
[23]GAO B,JEONG WI,TIAN Z.Liver:an organ with predominant innate immumity[J].Hepotology,2008,47(2):729-736.
|
|
[24]GAO B,RADAEVA S,PARK O.Liver natural killer and natural killer T cells:immunobiology and emerging roles in liver diseases[J].J Leukoc Biol,86(3):513-528.
|
|
[25]ADLER M,TAYLOR S,CKEBUGEU K,et al.Intrahepatic natural killer T cell populations are increased in human hepatic steatosis[J].World J Gastroenterol,2011,17(13):1725-1731.
|
|
[26]MAHER JJ,LEON P,RYAN JC.Beyond insulin resistance:innate immunity in non-alcoholic steatohepatitis[J].Hepatology,2008,48(2):670-678.
|
|
[27]ELINAV E,PAPPO O,SKLAIR-LEVY M,et al.Amelioration of non-alcoholic steatohepatitis and glucose intolerance in ob/ob mice by oral immune regulation towards liver-extracted proteins is associated with elevated intrahepatic NKT lymphocytes and serum IL-10 levels[J].J Pathol,2006,208(1):74-81.
|
|
[28]TANG T,SUI Y,LIAN M,et al.Pro-Inflammatory activated Kupffer cells by lipids induce hepatic NKT cells deficiency through activation-Induced cell death[J].PLo S One,2013,8(12):81949.
|
|
[29]COOL N,PONSAERTS P,van TENDELOO VF,et al.Regulatory T cells and human disease[J].Clin Dev Immunol,2007:89195.
|
|
[30]ROBERTSON FC,BERZOFSKY JA,TERABE M.NKT cell networks in the regulation of tumor immunity[J].Front Immunol,2014,5:543.
|
|
[31]GUO Y,LI W,YE AZ,et al.Study on chemotaxis of regulatory T cells induced by different antigents in mice[J].Chin J Immunol,2015,31(8):1032-1036.(in Chinese)郭音,李伟,叶艾竹,等.不同抗原诱导后小鼠调节性T淋巴细胞趋化特性动态研究[J].中国免疫学杂志,2015,31(8):1032-1036.
|
|
[32]VONGHIA L,MICHIELSEN P,FRANCQUE S.Immunological mechanisms in the pathophysiology of non-alcoholic steatohepatitis[J].Int J Mol Sci,2013,14(10):19867-19890.
|
|
[33]CIPOLLETTA D,FEUERER M,LI A,et al.PPAR-γis a major driver of the accumulation and phenotype of adipose tissue Treg cells[J].Nature,2012,486(7404):549-553.
|
|
[34]ILAN Y.Immune therapy for non-alcoholic steatohepatitis:are we there yet?[J].J Clin Gastroenterol,2013,47(4):298-307.
|
|
[35]ZHOU LL.The expression of Th 17 related with cytokine in NAFLD[D].Fujian Med Univ,2014.(in Chinese).周丽丽.Th17细胞及相关细胞因子在非酒精性脂肪肝模型中的表达[D].福建医科大学,2014.
|
|
[36]SUTTI S,JINDAL A,LOCATELLI I,et al.Adaptive immune responses triggered by oxidative stress contribute to hepatic inflammation in NASH[J].Hepatology,2014,59(3):886-897.
|
|
[37]TANG Y,BIAN Z,ZHAO L,et al.Interleukin-17 exacerbates hepatic steatosis and inflammation in non-alcoholic fatty liver disease[J].Clin Exp Immunol,2011,166(2):281-290.
|
|
[38]MARINONI B,CERIBELLI A,MASSAROTTI MS,et al.The Th17 axis in poriatic disease:pathogenetic and therapeutic implications[J].Auto Immun Highlights,5(1):9-19.
|
DownLoad: